AbbVie Inc. $ABBV Shares Purchased by Blair William & Co. IL

Blair William & Co. IL increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 5.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,337,461 shares of the company’s stock after buying an additional 73,880 shares during the period. AbbVie comprises 0.8% of Blair William & Co. IL’s investment portfolio, making the stock its 23rd largest holding. Blair William & Co. IL owned approximately 0.08% of AbbVie worth $305,596,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Graham Capital Management L.P. grew its stake in shares of AbbVie by 4.1% in the fourth quarter. Graham Capital Management L.P. now owns 7,152 shares of the company’s stock worth $1,634,000 after acquiring an additional 284 shares in the last quarter. Nicholas Wealth LLC. increased its position in shares of AbbVie by 11.5% during the fourth quarter. Nicholas Wealth LLC. now owns 5,291 shares of the company’s stock worth $1,209,000 after acquiring an additional 547 shares during the period. Silver Grove Financial Group Inc. raised its stake in shares of AbbVie by 15.2% in the fourth quarter. Silver Grove Financial Group Inc. now owns 1,798 shares of the company’s stock valued at $411,000 after acquiring an additional 237 shares in the last quarter. Elefante Mark B boosted its holdings in AbbVie by 24.4% in the fourth quarter. Elefante Mark B now owns 4,340 shares of the company’s stock valued at $992,000 after purchasing an additional 850 shares during the period. Finally, Militia Capital Partners LP purchased a new position in AbbVie in the fourth quarter valued at $274,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

ABBV opened at $222.62 on Wednesday. AbbVie Inc. has a one year low of $181.73 and a one year high of $244.81. The company has a market cap of $393.33 billion, a P/E ratio of 109.67, a PEG ratio of 0.68 and a beta of 0.32. The business’s 50-day simple moving average is $211.58 and its 200-day simple moving average is $218.89.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.46 earnings per share. As a group, analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABBV. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a research note on Thursday, April 30th. Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 7th. Finally, Canaccord Genuity Group lifted their price target on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.